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Abstract
Background: Age-related macular degeneration (AMD) is a prevalent cause of blindness in Western societies. Variants in the
genes encoding complement factor H (CFH), complement component 3 (C3) and age-related maculopathy susceptibility 2
(ARMS2) have repeatedly been shown to confer significant risks for AMD; however, their role in disease progression and thus
their potential relevance for interventional therapeutic approaches remains unknown.
Methodology/Principal Findings: Here, we analyzed association between variants in CFH, C3 and ARMS2 and disease
progression of geographic atrophy (GA) due to AMD. A quantitative phenotype of disease progression was computed
based on longitudinal observations by fundus autofluorescence imaging. In a subset of 99 cases with pure bilateral GA,
variants in CFH (Y402H), C3 (R102G), and ARMS2 (A69S) are associated with disease (P = 1.661029, 3.261023, and
P= 2.6610212, respectively) when compared to 612 unrelated healthy control individuals. In cases, median progression rate
of GA over a mean follow-up period of 3.0 years was 1.61 mm2/year with high concordance between fellow eyes. No
association between the progression rate and any of the genetic risk variants at the three loci was observed (P.0.13).
Conclusions/Significance: This study confirms that variants at CFH, C3, and ARMS2 confer significant risks for GA due to
AMD. In contrast, our data indicate no association of these variants with disease progression which may have important
implications for future treatment strategies. Other, as yet unknown susceptibilities may influence disease progression.
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Introduction
Age-related macular degeneration (AMD [MIM 603075]) is the
leading cause of blindness in Western countries [1]. Two major
forms of advanced AMD are responsible for vision loss.
Geographic atrophy (GA) or ‘‘dry’’ AMD is characterized by an
extensive loss of the choriocapillaris and the overlying retinal
pigment epithelium, while the neovascular form or ‘‘wet’’ AMD
develops due to invasion of neovascular complexes, a process
known as choroidal neovascularization (CNV) [2–4]. Although
constituting only 10–15% of all AMD cases, CNV accounts for
almost 80% of AMD-related blindness. Nevertheless, with an
increasingly aging population, blindness due to GA is predicted to
become a significant socioeconomic burden in the near future
[5–7]. To date, successful therapeutic intervention is available only
for active CNV, while GA still remains untreatable [8,9].
AMD is a complex condition with both genetic and environmen-
tal factors contributing to disease [2,3,10,11]. Genetic variants at two
chromosomal loci, 1q31 [12–15] and 10q26 [16,17] confer major
disease risks, together likely accounting for over 50% of cases.
Chromosome 1q31 association is tightly linked to the complement
factor H (CFH) gene suggesting an important role of inflammation
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and the alternative pathway of complement in AMD pathogenesis.
This is further supported by strong association of AMDwith variants
in the complement component 3 (C3 [MIM 120700]) gene [18,19].
At 10q26, variants at two genes in strong linkage disequilibrium,
namely age-related maculopathy susceptibility 2 (ARMS2 [MIM
611313]) [17,20] and HtrA serine peptidase 1 (HTRA1 [MIM
602194]) [21,22], were strongly linked to AMD susceptibility.
Further studies will be needed however to clarify which of the two
candidates plays the causal role in AMD pathology.
Going beyond cross-sectional association between AMD and
genetic variants, Seddon et al. reported a significant association
between the polymorphisms CFH-Y402H and ARMS2-A69S and
progression from early or intermediate stages of AMD to the
advanced forms [23]. It should be noted, however, that this study
has not addressed the question of whether genetic variants are
associated with disease progression once late AMD has developed.
Nevertheless, it is the progression of the two late forms, GA and
CNV, which is the most important variable with regard to future
therapeutic intervention.
A quantitative measure of geographic atrophy progression
represents the detection and quantification of atrophic areas on the
fundus at different time points in order to calculate atrophy
enlargement rates over time. The gold standard to define such areas
has been fundus photography; however, the reproducibility for
defining and measuring GA by fundus photography has been
reported by several groups to be only moderate, particularly for
smaller lesions [24–27]. An attractive alternative for non-invasive
imaging of atrophy and its progression over time is fundus
autofluorescence (FAF) imaging with the confocal scanning laser
ophthalmoscope (cSLO). This method potentially allows direct
visualization of loss of key cells in the disease process by tracing
metabolic RPE changes. Therefore, areas of GA can now reliably be
mapped facilitating absolute quantification of atrophic areas and their
progression in the disease process [28]. Here, we used FAF imaging
for phenotyping patients with GA in a longitudinal study, analyzed
GA progression and correlated this biologically-based quantitative
phenotype with genetic variants in the CFH, C3, and ARMS2 genes.
Results
Among the 619 participants of the FAM study cohort, 136 ex-
hibited GA with no sign of CNV throughout subsequent follow-up
examinations. Of these, 99 patients exhibited pure GA in both
eyes throughout the study period and were included in the further
analysis (for a comprehensive compilation of the phenotypic and
genotypic data, see Table S1). Mean follow-up was 3.0 years (SD,
2.1; range, 6 months to 10 years). Mean number of measurements
of GA area was 3.3 per eye (range, 2 to 12) and 3.5 per patient
(range, 2 to 12). Mean age of patients was 71.867.4 years (range,
53–89 years) and 76.265.3 years (range, 65–97 years) for the
controls (p,0.0001; t-test). Overall, 61% of the AMD patients and
62% of the controls were female (p = 0.837). Considering the most
general measurement of smoking history as a binary ‘‘ever or
never’’ variable, AMD patients were significantly more likely to
smoke than controls (49% versus 13%; p,0.0001).
In a case-control association analysis (N=99 cases of pure
bilateral GA; N=612 controls), polymorphisms Y402H
(rs1061170) in CFH, A69S (rs10490924) in ARMS2 and R102G
(rs2230199) in the C3 gene were strongly associated with GA due
to AMD (Table 1). In a case-only analysis (N=99 GA cases), the
median growth rate of GA was 1.61 mm2/year (interquartile
range [IQR], 1.19 to 2.12; range, 0.26 to 3.45), which is very
similar to our previous report [28]. A typical example of serial FAF
images over a study period of 109 months is shown in Figure 1.
Median GA area at baseline was 6.50 mm2 (IQR, 3.26 to 11.03;
range, 0.05 to 34.6). As a measure of concordance of the GA
progression rate between the right and left eye, the concordance
correlation coefficient [29] was calculated at 0.726, 95% CI
[0.587; 0.8297] indicating a high intra-individual symmetry of the
GA progression rate in our cohort.
To visualize the distribution of GA growth rate for individual
genotypes of CFH (Y402H), ARMS2 (A69S), and C3 (R102G),
patients were grouped for genotypes of these three major risk
genes (Figure 2). The association between the quantitative trait
variable ‘‘GA progression’’ and SNP alleles in the CFH, ARMS2
and C3 genes was then analyzed (Table 2). Adjusting for age,
smoking history and body mass index (BMI), and after a Sidak
correction for multiple testing, none of the single-marker P values
remained significant at alpha= 0.05. Similarly, there was no
significant association between GA progression and the Y402H
(rs1061170) and I62V (rs800292) haplotype of CFH (Table 2).
Power calculations revealed a power of 80% (at alpha= 0.05) for
detecting an additive allele effect of 0.278 mm2/year (Y402H,
CFH), 0.275 mm2/year (A69V, ARMS2) and 0.292 mm2/year
Table 1. SNP association in 99 AMD patients with bilateral pure GA versus 612 matched controls.
Gene (Marker) Group Genotypes (Frequency) MAF ATT P-value
CFH (rs1061170) T/T T/C C/C
Cases 18 (0.184) 42 (0.429) 38 (0.388) 0.602
Controls 214 (0.350) 327 (0.535) 70 (0.115) 0?382
Odds Ratio [95% CI] 1 [Ref.] 1.53 [0.86,2.72] 6.45 [3.46,12.03] 1.6361029
ARMS2 (rs10490924) G/G G/T T/T
Cases 36 (0.364) 42 (0.424) 21 (0.212) 0.424
Controls 402 (0.658) 184 (0.301) 25 (0.041) 0.191
Odds Ratio [95% CI] 1 [Ref.] 2.55 [1.58,4.11] 9.38 [4.79,18.39] 2.58610212
C3 (rs2230199) G/G G/C C/C
Cases 54 (0.557) 35 (0.361) 8 (0.082) 0.263
Controls 394 (0.675) 176 (0.301) 14 (0.024) 0.175
Odds Ratio [95% CI] 1 [Ref.] 1.45 [0.92,2.30] 4.17 [1.67,10.40] 0.0032
Abbreviations: MAF, minor allele frequency; ATT, Armitage’s trend test; CI, confidence interval.
doi:10.1371/journal.pone.0007418.t001
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(R102G, C3), respectively. There was 95% power to detect an
effect of less than 0.4 mm2/year for any of the three genetic risk
factors. A detailed power calculation is given in Table S2.
Discussion
Here, we demonstrate a significant association between our
study group with late AMD manifestations of pure GA and known
variants at CFH, C3, and ARMS2. The odds ratios for
heterozygotes and homozygotes for any of the three genes are
highly consistent with previous reports [18,19,30]. Those reports
typically included mixed study populations including both forms of
late AMD, CNV and GA. This was also true for recent reports of
R102G in C3 as a significant risk variant for AMD where similar
results were found for CNV and GA [18,19]. DeWan and co-
workers reported HTRA1 as a risk gene for CNV due to AMD,
implicating that polymorphisms in the ARMS2-HTRA1 region are
responsible for this specific phenotype of late AMD. This is a
surprising notion since others, including our own study, did not
find any difference in the association data between GA and CNV
due to AMD [17]. Our current data now unambiguously
demonstrate that the risk for GA is similarly associated with
ARMS2-HTRA1 variants and suggests that the association between
the CFH and ARMS2 polymorphisms is independent of disease
evolution towards the atrophic or the neovascular form of AMD.
A significant original finding of this study is that none of the
AMD-associated polymorphisms in CFH, C3 and ARMS2
contribute to GA progression once GA has developed. It is of
note that our analysis had good power to detect an additive allele
effect of less than 0.3 mm2 of GA progression per year. A GA
progression rate of 0.3 mm2 or less represents a relatively small
effect with less than 1/5 of the mean effect in our study population.
Moreover, it is clearly below the threshold of recent phase II
studies with therapeutic intervention in GA (e.g. fenretinide trial;
ClinicalTrials.gov identifier: NCT00429936) which aim to slow
GA progression by at least 0.6 mm2/year.
Although the number of patients (N= 99; baseline, N= 619)
may appear limited, the significance of this study mainly originates
from its dependency on the major outcome variable which is a
biologically based continuous variable. To put the size of our
patient study group into perspective, the major population-based
studies such as the Beaver Dam Eye Study as well as the major
clinical trial sponsored by the National Eye Institute (e.g. Age-
Related Eye Disease Study, AREDS) all include similarly limited
numbers of longitudinally phenotyped patients with pure bilateral
GA. Specifically, AREDS has 70 such patients (baseline, N= 3640)
[31], while the Beaver Dam Eye Study has only 27 patients of at
least 5-year follow-up (baseline, N=4926; Ronald Klein, personal
communication).
The strength of the current data is based on the phenotypic
assessment of GA by cSLO-based FA imaging, semi-automated
image analysis and complex statistics condensing longitudinal data
into one continuous phenotypic variable. Although its accuracy
may improve with the number of measurements over time, we
have previously shown that GA progression is linear, which makes
two consecutive measurements sufficient to estimate GA growth
rate, although the number of longitudinal observations improves
the accuracy of the estimated GA progression rate. [28,32] An
additional strong point in this study is the substantial number of
patients with bilateral pure GA recruited through the multicenter
FAM study.
Strong linkage disequilibrium (LD) across the ARMS2-HTRA1
region makes it difficult to distinguish between ARMS2 [16,17] and
HTRA1 [21,22] as causal factors in AMD pathogenesis. We
recently identified a deletion-insertion polymorphism in ARMS2
(*372_815del443ins54) that is in almost perfect LD with the A69S
variant and directly affects the stability of the transcript by
removing the polyadenylation signal and inserts a 54-bp element
known to mediate rapid mRNA turnover. [20] Immunohisto-
chemistry has associated ARMS2 with mitochondria [33],
specifically within the photoreceptor inner segments [20],
suggesting that mechanisms of mitochondrial dysfunction may
be involved in AMD pathogenesis.
Experimental [34] and clinical [35] data propose a key role of
the major lipofuscin fluorophore A2-E in GA progression.
Interestingly, A2-E biogenesis was recently linked to complement
activation [36]. There is now compelling evidence that the
complement system is involved in the pathogenesis of AMD and
that the Y402H variant of CFH is associated with AMD
susceptibility. Our data confirm this finding specifically for GA.
Recently, we have detected systemic complement activation in
AMD and found that markers of chronic complement activation
were associated with the CFH risk haplotype (including the Y402H
polymorphism). [37] However, since the Y402H variant of CFH
confers similar risk of soft drusen and both forms of advanced
AMD, it may contribute to the increased risk of advanced AMD
largely or entirely through its impact on precursors of visually
disabling AMD such as drusen. [38] Since polymorphisms in CFH,
C3, and ARMS2 are not associated with progression of GA and
since our previous analysis did not detect a significant contribution
of other characteristics (including smoking and BMI) [28] other
modifying genetic factors may be involved.
Our findings may have strong implications for future efforts to
design therapeutic interventions for AMD, although replication in
Figure 1. Progression of GA in a patient with age-relatedmacular degeneration over a period of nine years. Atrophic areas are outlined
in each image. Baseline GA area was 4.3 mm2; GA progression rate was 1.50 mm2/year based on 12 observations within nine years of clinical follow-
up. GA growth rate of the fellow eye was 1.59 mm2/year. The patient’s genotype was C/T for CFH-rs1061170, G/G for ARMS2-rs10490924, and C/G for
C3-rs2230199.
doi:10.1371/journal.pone.0007418.g001
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an independent cohort and empirical treatment data are needed
for further substantiation. Since variants within CFH, C3, and
ARMS2 confer risk for susceptibility of GA but appear unrelated to
its progression, addressing the complement cascade or ARMS2-,
and possibly HTRA1-associated pathways per se may not be
promising strategies for alleviating disease progression once GA
has developed. Instead, defining the exogenic and possibly the
genetic factors responsible for GA progression could be crucial in
helping those patients already suffering from advanced stages of
the disease.
Methods
Ethics Statement
The study followed the tenets of the Declaration of Helsinki and
was approved by the local Ethics Review Board at the University
of Bonn. Informed written consent was obtained from each patient
after explanation of the nature and possible consequences of the
study.
Cases and Controls
Patients with GA secondary to AMD were included from the
longitudinal natural history arm of the multicenter FAM–Study
(Fundus Autofluorescence in Age-Related Macular Degeneration;
registration www.clinicaltrials.gov: NCT00393692). The study
procedures have been previously reported. [28,39] A total of
619 patients with dry (early or late) AMD in the study eye were
enrolled (mean age, 73.9 years; mean follow-up, 35 months) and
were recruited at six centres throughout Germany. Because of
differences in genotype frequencies due to race and geographical
origin, only white probands originating exclusively from Germany
were included in the study.
Patients with uni- or multifocal GA and with clear vitreous to
allow FAF imaging were included in the analysis. Exclusion
criteria were a history of retinal surgery, laser photocoagulation
and radiation therapy or other retinal diseases in the study eye
such as diabetic retinopathy or hereditary retinal dystrophies.
Fluorescein angiography was only performed if funduscopic signs
were present indicative of neovascular AMD in addition to patches
of GA. Such eyes were excluded from further analysis.
612 unrelated control individuals of German origin served as
controls for case-control analysis to investigate the role of variants
in CFH, C3 and ARMS2 for AMD susceptibility. [17] Each
control subject underwent a single ophthalmic examination
including visual acuity, slit lamp biomicroscopy and fundus
ophthalmoscopy. Patients and controls underwent a general
health interview protocol including a standardized smoking
history.
Phenotyping by FAF Imaging
FAF was measured using a confocal laser scanning ophthalmo-
scope (cSLO; Heidelberg Retina Angiograph, HRA classic and
HRA 2, Heidelberg Engineering, Dossenheim, Germany), the
optical and technical principles of which have been described
previously. [40] An argon blue laser (HRA classic) or optically
pumped solid state laser (HRA 2) were used for excitation (both
488 nm). The emitted light above 500 nm was detected with a
barrier filter. FAF images were recorded in accordance with
standard operating procedures (SOP) including focussing in the
blue reflection mode, acquisition of a series of 30u630u images
(488 nm) and calculation of mean images after automated
alignment in order to amplify signal to noise ratio with image
analysis software (Heidelberg Eye Explorer, Heidelberg Engineer-
ing, Dossenheim, Germany). [41]
Figure 2. Growth rates of geographic atrophy for the
subgroups of AMD patients grouped by genotypes for the
three major risk alleles, CFH (A), ARMS2 (B), and C3 (C). Shown are
the median (central bar), the 25th and 75th percentiles (grey box), the 5th
and 95th percentiles (bars) and the minimum and maximum (small
circles).
doi:10.1371/journal.pone.0007418.g002
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Only patient eyes with at least two follow-ups in a 6 month
interval and with sufficient image quality to accurately determine
the size of atrophy were included. To further improve on our
previous analytical strategy [28,32], serial FAF images of the same
eye were aligned by the ‘‘4-point-alignment’’ function using Picture
Window Pro 4.0.1.2 analysis software (Digital Light & Color,
Cambridge, MA, USA). The total size of GA was measured in the
processed FAF images by automated imaging analysis software that
uses region-growing techniques to segment the areas of GA. [42]
This procedure significantly reduced the estimated within-group
error variance from 0.761 mm2/year, 95% CI [0.645; 0.898]
previously [32] to 0.212 mm2/year, 95% CI [0.182; 0.246].
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes
according to established protocols. Genotyping was done by
TaqMan SNP Genotyping or by the matrix-assisted laser
desorption/ionization time of flight (MALDI-TOF) mass spec-
trometry method (Sequenom, San Diego, CA, USA). TaqMan
Pre-Designed SNP Genotyping Assays (Applied Biosystems, Foster
City, CA, USA) were performed according to the manufacturer’s
instructions and were analyzed with a 7900HT Fast Real-Time
PCR System (Applied Biosystems). All SNPs showed high
genotyping quality with an average call rate of 98.5%.
Statistical Analysis
Data management and statistical analysis were conducted using
SAS Version 9.1.3 (Cary, NC, USA). The statistical analyses were
carried out using software package R, Version 2.7.0 (http://www.
r-project.org/), and the R-library ‘‘non-linear mixed effects’’
(NLME) was applied for hierarchical regression modelling. A
linear mixed effects model was used to quantify GA growth. A
detailed description of the longitudinal modelling process is
provided elsewhere. [32,43] The two-level-random effects model
separates ocular-specific as well as patient-specific effects and helps
to handle related observations. The mixed model methodology
allows the study of variance components and fixed effects
simultaneously. Using this two-level-random effects model, a
single variable of GA progression rate was computed based on
longitudinal observations of either one or both eyes for each
patient studied. [32] This variable represents a continuous,
biology-based quantitative phenotype and was used for association
analysis with genetic data.
We used the case-control tool box from FAMHAP to perform
quality control of the genetic data. [44] SNP genotypes in cases
and controls showed no deviation from Hardy-Weinberg-Equilib-
rium at a level of alpha= 0.001. UNPHASED [45] was used to test
for association between the quantitative trait variable ‘‘GA
progression’’ and SNP alleles and haplotypes. We adopted the
standard practice of genetic epidemiological studies to test in an
allele-based manner when the underlying disease model is
unknown. This has the advantage of reducing the number of
degrees of freedom to 1. Although the resulting test is additive by
nature, it is the most powerful test under a much broader range of
true disease scenarios. The UNPHASED program provides P
values as well as additive effect estimators for the effects of alleles/
haplotypes on the quantitative trait. The reference alleles represent
the respective major SNP alleles within Caucasian populations.
The respective confidence intervals are provided as well. We also
adjusted for the covariates age, BMI, and smoking, using the
‘‘modifiers’’ option of the UNPHASED software package. Posthoc
power values for a t-test as an approximation of power for
quantitative trait analysis for single SNPs were computed with the
R software package, with the two groups of the t-test constituting
the two alleles and the group sizes the allele counts. Covariates
were not accounted for in the power calculation. Since the disease-
associated allele is known, one-sided power values were computed.
Table 2. Association between the quantitative trait variable ‘‘geographic atrophy progression’’ and SNP alleles and haplotypes.
Gene (Marker)
Allele/
Haplotype
Frequency
(N=99)
Additive Allele Effect
in mm2/year (95% CI)a
P valueb
(unadjusted)
P valueb (adjusted for
age, smoking and BMI)
P valueb (corrected
for multiple testingc)
CFH (rs800292) G 172 (0.89) Reference
A 22 (0.11) 0.0963 (20.50, 0.70)
0.377 0.425 0.937
CFH (rs1061170) T 78 (0.40) Reference
C 118 (0.60) 0.2055 (20.19, 0.60)
0.156 0.097 0.4
CFH (rs800292–rs1061170) G–T 55 (0.29) Reference
G–C 115 (0.60) 0.3048 (20.15, 0.75)
A–T 22 (0.11) 0.3301 (20.36, 1.02)
0.376d 0.204d 0.68
ARMS2 (rs10490924) G 114 (0.58) Reference
T 84 (0.42) 0.0776 (20.31;0.47)
0.233 0.376 0.905
C3 (rs2230199) G 143 (0.73) Reference
C 51 (0.26) 20.5141 (20.98, 20.05)
1 1 1
aProgression rates relative to the reference allele/haplotype (non risk) which was set by definition to 0 mm2/year.
bTesting for a positive trend of progression (one-sided test).
cSidak correction for five tests (4 SNPs and haplotype test).
dTwo-sided test.
doi:10.1371/journal.pone.0007418.t002
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Supporting Information
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with late-stage AMD
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